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Transplantation of stem cells represents an upcoming therapy for many degenerative 
diseases. For clinical use, transplantation of pluripotent stem cell-derived cells should 
lead to integration of functional grafts without immune rejection or teratoma formation. 
Our previous studies showed that the risk of teratoma formation is highly influenced by 
the immune system of the recipients. In this study, we have observed a higher teratoma 
formation rate when undifferentiated so-called multipotent adult germline stem cells 
(maGSCs) were transplanted into the heart of T, B, and natural killer (NK) cell-deficient 
RAG2−/−γc−/− mice than in RAG2−/− mice, which still have NK cells. Notably, in both 
strains, the teratoma formation rate was significantly reduced by the immunosuppressive 
drug cyclosporine A (CsA). Thus, CsA had a profound effect on teratoma formation inde-
pendent of its immunosuppressive effects. The transplantation into RAG2−/− mice led to 
an activation of NK cells, which reached the maximum 14 days after transplantation and 
was not affected by CsA. The in vivo-activated NK cells efficiently killed YAC-1 and also 
maGSC target cells. This NK cell activation was confirmed in C57BL/6 wild-type mice 
whether treated with CsA or not. Sham operations in wild-type mice indicated that the 
inflammatory response to open heart surgery rather than the transplantation of maGSCs 
activated the NK cell system. An activation of NK cells during the transplantation of stem 
cell-derived in vitro differentiated grafts might be clinically beneficial by reducing the risk 
of teratoma formation by residual pluripotent cells.
Keywords: tumorigenicity, multipotent adult germline stem cells, microenvironment of the heart, natural killer 
cells, cyclosporine a, cell transplantation
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inTrODUcTiOn
Pluripotent stem cell (PSC)-based cellular transplantation 
represents an upcoming therapy for many degenerative diseases 
such as heart failure (1, 2). Embryonic stem cells (ESCs) are 
pluripotent and are able to differentiate into derivatives of the 
three embryonic germ layers. Therefore, they could be used to 
obtain a broad variety of cellular grafts including cardiomyocytes 
or cardiac tissues for cellular therapies (3). However, the estab-
lishment of human ESC-based cellular therapies causes consider-
able ethical concerns due to the need to destroy blastocysts for 
generating ESCs. In the past decade, many efforts have been made 
to generate induced pluripotent stem cells (iPSCs) by genetically 
manipulating somatic cells (4–6). The iPSCs overcome the ethical 
concerns associated with ESCs. We have shown that mouse adult 
spermatogonial stem cells (SSCs) are able to be converted into 
so-called multipotent adult germline stem cells (maGSCs), which 
exhibit similar differentiation properties as ESCs, by modifying 
the culture conditions of the SSCs without the need of any genetic 
manipulation (7). These PSCs provide us the opportunity to study 
on an alternative PSC-based cellular therapy for the future clini-
cal application (8).
For clinical use of PSCs, one of the critical issues is the risk of 
teratoma formation after transplantation of desired differentiated 
cells that might contain traces of PSCs (9). Generally, the risk of 
teratoma formation associated with PSCs is due to their prolif-
eration and differentiation capacity. It is widely debated whether 
the procedures used for the generation of iPSCs further increase 
the risk of tumor formation (10, 11). For allogeneic and perhaps 
even for syngeneic transplantations (due to the expression of 
developmental antigens or neo-antigens) of PSC-derived grafts, 
another issue is immune rejection of the transplanted cells (12). 
Although terminally differentiated PSC-derived syngeneic cells 
are apparently accepted in recipients (13–15), the immunogenic-
ity of therapeutically relevant autologous grafts was reported to 
differ depending on the cell types into which human iPSCs have 
been differentiated (16).
Early studies showed that injection of undifferentiated murine 
ESCs, iPSCs, or maGSCs into immunodeficient or syngeneic 
mice led to teratoma formation, demonstrating engraftment (7, 
17–22). When mouse or human ESCs or iPSCs were injected into 
immunocompetent allogeneic or xenogeneic mice, respectively, 
they were rejected by the immune system and no teratoma 
formation was observed (20, 23, 24). In a previous study, we 
observed a failure of engraftment after allogeneic transplantation 
of ESCs subcutaneously in immunocompetent mice (0 out of 32 
mice) and a rare engraftment, i.e., tumor formation (1 out of 27 
mice) in mice treated with cyclosporine A (CsA) (20). CsA, a 
calcineurin inhibitor, is one of the most commonly used immu-
nosuppressive drugs after solid organ transplantation. It inhibits 
the production of interleukin (IL)-2, thus suppressing the activa-
tion of alloreactive T lymphocytes (25). Notably, after allogeneic 
transplantation of mouse ESCs into the heart, teratomas were 
observed even in immunocompetent mice not treated with CsA 
or other immunosuppressive drugs (18). However, when we 
injected maGSCs into the heart of immunocompetent allogeneic 
mice immunosuppressed daily with CsA, no teratomas were 
found within 4  weeks (8). These data suggest that besides the 
immune system of the recipients, the source, quality, and dif-
ferentiation state of the injected cells exert huge influence on the 
transplantation outcome and specifically on the risk of teratoma 
formation.
Different elements of the immune system could be responsible 
for the rejection of transplanted PSCs. In addition to T lympho-
cytes (23, 26), natural killer (NK) cells play an important role 
in the rejection of stem cell grafts (20–22, 27, 28). Our previous 
studies showed that mouse PSCs, including ESCs, iPSCs, and 
maGSCs, are targets for allogeneic and syngeneic IL-2-activated 
NK cells in vitro (20, 22). Moreover, NK cells impair the growth of 
teratomas after subcutaneous injection of PSCs, including ESCs, 
iPSCs, and maGSCs (20, 22, 29). Similarly, human iPSCs are 
targets for allogeneic and syngeneic IL-2-activated NK cells (30). 
NK cells are often described as first-line defense against infected 
or malignant cells, which act without the need of prior activation. 
However, the regulation of NK cell activity is now known to be 
much more complex (31).
Natural killer cells might be important after transplantation of 
grafts derived from PSCs because they could have the ability to 
reject residual PSCs, which might contaminate grafts in very low 
numbers, despite all efforts to eliminate undifferentiated cells by 
various means (29). Differentiated cells, in contrast, are expected 
to have the ability to inhibit NK cells and should therefore not 
become a target of these cytotoxic cells (22). However, so far, it 
is not known whether transplantation of allogeneic PSCs can 
activate NK cells in recipients receiving a treatment, e.g., with 
CsA, to suppress the immune system.
In the present study, we show that the NK cell cytotoxicity 
was increased after transplantation of maGSCs into the hearts 
of B and T cell-deficient, immunocompetent, and CsA-treated 
immunosuppressed recipients. The cardiac operation proce-
dure alone was sufficient to activate NK cells against the PSCs. 
Moreover, NK cells reduced the frequency of teratoma formation 
after transplantation of maGSCs into the heart. Notably, CsA had 
an independent effect on the maGSCs, which further reduced the 
risk of teratoma formation in the recipients.
MaTerials anD MeThODs
cell culture
Mouse maGSCs (line SSC5) were cultured on mitomycin 
C-inactivated mouse embryonic feeder cells in Dulbecco’s modi-
fied eagle medium (DMEM; Thermo Fisher Scientific) supple-
mented with 15% fetal calf serum (FCS; selected batch, Lonza), 
glutamine (2  mM, Thermo Fisher Scientific), 1× non-essential 
amino acids (Thermo Fisher Scientific), β-mercaptoethanol 
(β-ME; 50 µM, Promega), and 103 U/ml leukemia inhibitor fac-
tor (Millipore) as described previously (7). The cells have been 
derived from a mouse with a mixed FVB (H2q), C57BL/6 (H2b), 
and 129Sv (H2b) genetic background (7). For in vivo studies, the 
maGSCs were separated from the mouse embryonic feeder cells 
before use. The maGSCs were obtained by collecting the floating 
cells after being cultivated for 1 h on culture dishes coated with 
0.1% gelatin (Sigma-Aldrich: Fluka).
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The murine T-lymphoma cell lines YAC-1 (H2a), which was 
used as positive control for the cytotoxic activity of NK cells, and 
RMA (H2b) were maintained in DMEM supplemented with 10% 
FCS, 2  mM glutamine, 1  mM sodium pyruvate, 50  µM β-ME, 
100 U/ml penicillin, and 100 µg/ml streptomycin.
intramyocardial injection of magscs
Following mice strains were used in the study: C57BL/6 wild-
type mice, immunodeficient RAG2−/− mice that have no B and T 
lymphocytes, and RAG2−/−γc−/− mice that are deficient of B and T 
lymphocytes and NK cells. All animal experiments were carried 
out in compliance with EU legislation (Directive 2010/63/EU). 
The animal experiments for transplantation of maGSCs into the 
heart were approved by Lower Saxony State Office for Animal 
Welfare (Az: 33.425.2-010/06) and for subcutaneous injection of 
maGSCs by Lower Saxony State Office for Consumer Protection 
and Food Safety (Az: 33.14.42502-04-113/09).
Mouse maGSC SSC5 cells were injected in the anterolateral 
wall of the heart as described previously (8). Briefly, mice were 
anesthetized with isoflurane, intubated with a 22 gauge (G) 
plastic cannula and ventilated with a mixture of 2% isoflurane 
in ambient air (150 breaths/min, tidal volume 150 µl) by use of a 
MiniVent (Type 845, Harvard Apparatus). The heart was exposed 
by a left lateral thoracotomy via the fourth intercostal space and 
the pericardium was opened. Undifferentiated maGSCs (3 × 105) 
were injected in a volume of 20 µl by use of a 30G steel cannula 
connected to a 50 µl Hamilton syringe via a PE10 tube. The total 
volume was applied in four injections of 5 µl each covering the 
area of the anterolateral wall of the heart that was accessible via 
the thoracotomy. Afterward, the thorax was closed with single 
sutures before the skin was adapted with polypropylene 6-0 
sutures. After surgery, the mice received buprenorphine (0.1 mg/
kg body weight, intraperitoneal injection) for pain relief and were 
placed on a heating pad to recover until fully awake. Metamizole 
(1.33 mg/ml) was provided with the drinking water to the mice 
for postoperative analgesia for a week.
The mice were sacrificed at different time points, i.e., 3, 7, 14, 
or 28 days after the cell transplantation (Tx) and the hearts and 
spleens were taken out for histological or immunological analyses, 
respectively. Blood was collected to obtain serum that was stored 
at −20°C until used for cytokine measurements. The mice were 
inspected for tumors at other sites except for the heart. If present, 
such tumors were taken out for further histological analyses.
histological studies
The hearts and tumors found at other sites of the body were 
fixed in phosphate-buffered formalin (30 mM NaH2PO4, 40 mM 
Na2HPO4, 4% formalin) for 4 h at room temperature. The tissues 
were then washed three times with distilled water, embedded in 
paraffin, and cut into 6 µm thin sections, which were examined 
with hematoxylin and eosin (H&E) staining on an automated 
immunostainer (Ventana Medical Systems) according to the 
manufacturer’s protocol.
For immunohistological analysis, deparaffinized sections 
were boiled in citrate buffer (DakoCytomation) for 15  min to 
recover the antigenicity. Afterward, the sections were incubated 
in 3% hydrogen peroxide for 10  min at room temperature to 
block endogenous peroxidases and in 4% bovine serum albumin 
(Thermo Fisher Scientific) for 30 min to block non-specific immu-
noreactivity. The sections were then treated with 0.2% Triton 
X-100 (Sigma) for 30  min before incubation with the primary 
antibody (anti-OCT4 monoclonal antibody, BD Biosciences, 
dilution 1:100) for 60 min at room temperature. OCT4 was then 
detected with commercial available SuperPicture™ Polymer 
Detection Kit (Thermo Fisher Scientific).
isolation of nK cells
For the analysis of NK cell cytotoxicity, the spleens were taken 
out and the NK cells were isolated by the magnetic-activated cell 
sorting using a kit (Miltenyi Biotec) to obtain untouched mouse 
NK cells by negative selection according to the manufacturer’s 
instruction. The purity of the isolated CD49b+CD3− NK cells was 
always determined by flow cytometry.
51chromium release assay
Target cells were labeled by incubating 1 × 106 maGSC SSC5 or 
YAC-1 cells with 200 µl of DMEM with 100 µl of FCS and 50 μCi 
Na251CrO4 (Hartmann Analytic) for 1 h at 37°C and then washed 
three times with DMEM. These 51Chromium-labeled target cells 
(5 × 103 per well of round-bottomed microtiter plates) were co-
cultivated with the isolated NK cells (effector cells) in triplicates 
at diverse effector–target ratios in 200 µl of DMEM containing 
10% FCS for 4 h at 37°C. The microtiter plates were centrifuged 
for 5 min at 40 g; supernatant and sediment were separately taken 
to determine radioactivity in each well using a Wallac MicroBeta 
Trilux counter (PerkinElmer Life Sciences). Spontaneous release 
was determined by incubating target cells without the effector 
cells. The percentage of specific lysis of the target cells was calcu-
lated as described previously (22, 32).
Flow cytometry
Flow cytometry was performed with a FACSCalibur flow 
cytometer and CellQuestPro software (BD Biosciences). The 
purity of isolated NK cells was analyzed using monoclonal anti-
bodies (mAbs) against CD49b and CD3. The Abs used for flow 
cytometry are described in Table S1 in Supplementary Material. 
Cell surface expression of CD112, CD155, RAE-1, H2Kb, H2Db, 
and H2Kq was determined on target cells. In some experiments, 
interferon (IFN)-γ (100 ng/ml, ImmunoTools) was added to the 
cells 48 h before analysis. Isotype controls were used for directly 
labeled mAbs. For staining, 2 × 105 cells were incubated in 100 µl 
PBS with 1 µg of the respective primary mAb for 30 min at 4°C 
before washing with PBS. To detect the unlabeled anti-CD112, 
anti-CD155, and anti-RAE-1 mAbs, the cells were incubated 
subsequently in 100 µl PBS with 1 µl of FITC-labeled anti-rat IgG 
Ab for 30 min. Cells stained with the secondary Ab only served 
as control.
enzyme-linked immunosorbent  
assay (elisa)
To measure the concentration of IL-1b, IL-4, IL-6, IL-17A, 
IFN-γ, and tumor necrosis factor (TNF)-α in sera of mice, we 
used ELISA MAX Standard Sets from Biolegend according to 
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the manufacturer’s instructions. The sera were diluted 1:2 for the 
measurement of IL-1b and TNF-α and 1:5 for the other cytokines. 
In the end, 50 µl 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) (ABTS) substrate solution was added to each well and 
the optical density was determined using a BioTek PowerWave 
340 microplate spectrophotometer (BioTek) set to 405 nm. All 
samples were analyzed in comparison to a standard curve of the 
respective cytokine.
statistical analysis
Results are shown as mean with SD or as mean with SEM for 
cytotoxicity assays. The data were evaluated with the GraphPad 
Prism 4.0 or 6.0 program or WinStat software (R. Fitch Software). 
The Kolmogorov–Smirnov test was used to determine normal 
distribution and Student’s t-tests or two-way-ANOVAs for 
subsequent analyses. The non-parametric Wilcoxon (U) or 
Kruskal–Wallis (H) tests were used to compare non-normally 
distributed target variables. Pearson’s chi-squared test (χ2) was 
used to analyze differences in sets of categorical data. A P-value of 
≤0.05 in two-sided tests was considered significant. Significance 
levels are shown in the following way, if not the exact P value is 
given: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
resUlTs
The Microenvironment of the heart Does 
not affect the Tumorigenicity of magscs
Our previous studies showed that undifferentiated maGSCs (line 
SSC5) could form teratomas in immunodeficient SCID mice 
within 6  weeks after subcutaneous injection (2 ×  106 cells per 
injection) (7) and the cells retained this capacity under differ-
ent culture conditions (21). However, when the SSC5 maGSCs 
(0.5–1 × 106 cells per injection) were injected into the heart of 
partially allogeneic C57BL/6 wild-type mice immunosuppressed 
daily with CsA (10 mg/kg body weight, i.p.), no engraftment and 
no teratomas were found within 4 weeks (8). Here, three questions 
were raised: (1) Does the microenvironment of the heart prevent 
the tumorigenicity of maGSCs? (2) Do NK cells play a role in the 
rejection of the PSCs in CsA-treated hosts? (3) Does the treat-
ment of the recipients with CsA affect the maGSCs directly?
To answer these questions, first we examined whether the 
microenvironment of the heart influences the tumorigenicity of 
undifferentiated maGSCs. The maGSC SSC5 cells (5 × 105 cells 
per injection) were transplanted directly into the myocardium of 
RAG2−/−γc−/− mice that are deficient in T and B lymphocytes as 
well as NK cells. All mice (n =  8) formed tumors in the heart 
within four weeks after transplantation (Table  1). The tumors 
contained derivatives of the three embryonic germ layers, includ-
ing intestinal epithelium (endoderm), striated muscles, cartilage 
(mesoderm), and neural tissues (ectoderm), and were therefore 
teratomas (Figures 1A–D). The teratomas showed a mean size of 
4.7 mm length and 3.9 mm width on average (Figure 1E). In addi-
tion, teratomas were also formed in the kidney, liver, or intestinal 
tissues in six out of eight mice (Table 1).
We also performed subcutaneous injections of the maGSC 
SSC5 cells into C57BL/6 wild-type mice. The cells (2 × 106 cells per 
injection) failed to form teratomas after subcutaneous injection 
in immunocompetent (n =  9) and in CsA-immunosuppressed 
(10 mg/kg/day) recipients (n = 9) within 15 weeks after trans-
plantation (Table 1). These data indicate that the microenviron-
ment of the heart has no specific influence on the engraftment 
or tumorigenicity of undifferentiated maGSCs. Teratomas were 
formed in immunodeficient recipients similarly in the subcutane-
ous tissue (7) and in the heart (Table 1), but engraftment failed 
at both sites in immunosuppressed but partially allogeneic hosts 
(Table 1). Since CsA mainly suppresses T cells, the results sug-
gested an effect of NK cells on engraftment of maGSCs.
Tumorigenic cells are Targets of nK  
cells after Transplantation
To investigate whether NK cells indeed have effects on the 
teratoma growth in the heart as they have after subcutaneous 
injections (22), we injected 5 × 105 undifferentiated maGSCs into 
the myocardium of RAG2−/− mice that are deficient in T and B 
lymphocytes but have functional NK cells. We detected tumors 
in the heart in five out of six mice 4 weeks after transplantation 
(Table 1). Compared to the tumors of the RAG2−/−γc−/− mice, the 
size of teratomas in RAG2−/− mice was smaller with a mean size 
of 3.6 mm length and 2.3 mm width (Figure 1E). In addition, 
only in two mice, tumors were also found in the kidney or in the 
chest. The tumors in RAG2−/− mice also contained derivatives of 
the three embryonic germ layers, including intestinal epithelium, 
striated muscles, cartilage, and neural tissues, and were therefore 
teratomas (data not shown). These results indicate that the NK 
cells in RAG2−/− mice partially suppress the teratoma formation 
in the heart and at distant sites of the injection.
We isolated NK cells from the spleens of the RAG2−/− mice 
(n = 3 per group) at different time points after transplantation 
of the maGSCs (days 3, 7, 14, and 28) and directly analyzed their 
cytotoxic activity against the SSC5 maGSCs and the NK target 
cell line YAC-1 in 51Chromium release assays. Mice not operated 
(day 0, n = 4) were used to determine the basal NK cell activity. 
The specific lysis of YAC-1 cells by NK cells of untreated mice was 
31% at an effector:target (E:T) ratio of 24:1, but only 13% for the 
maGSC SSC5 cells (Figure 2A). Thus, the maGSC SSC5 cells were 
more resistant to NK cells from control mice than the YAC-1 cells 
(P = 7.50 × 10−8, two-way ANOVA adjusted for E:T ratios). Also 
NK cells from transplanted mice killed more YAC-1 than maGSC 
SSC5 cells (overall: P =  7.44 ×  10−17; 7 days: P =  1.23 ×  10−10; 
14  days: P =  1.11 ×  10−11; 28  days: P =  4.41 ×  10−8) with the 
exception of the earliest time point after transplantation (3 days: 
P = 0.3709, two-way ANOVA adjusted for E:T ratios).
With exception of the earliest time point (3 days), the cytotoxic 
activity of the NK cells after transplantation of maGSC SSC5 cells 
into the heart was increased in comparison to those from non-
operated control mice (day 0). On average, the specific lysis of 
YAC-1 cells at an E:T ratio of 24:1 was 62% by NK cells from 
mice at day 7 (P = 0.0003 versus control mice, two-way ANOVA 
adjusted for E:T ratios), 69% at day 14 (P =  2.08 ×  10−8), and 
55% at day 28 after transplantation (P = 0.0063). Three days after 
transplantation, the cytotoxic activity of NK cells against YAC-1 
cells was reduced compared to control mice (P = 0.0015, two-way 
Table 1 | Frequency of teratoma formation after transplantation of multipotent adult germline stem cell (magsc) ssc5 cells.
recipient 
strain
site of 
transplantation
number of 
transplanted cells
−csa +csa Duration of 
experiment 
(weeks)Tumor at site of 
injection
Tumor at distant 
site
Tumor at site of 
injection
Tumor at distant 
site
RAG2−/−γc−/− Heart 5 × 105 100% (8/8) 75% (6/8) 60% (3/5) 0% (0/5) 4
RAG2−/− Heart 5 × 105 83% (5/6) 33% (2/6) 20% (1/5) 0% (0/5) 4
C57BL/6 Heart 5 × 105 0% (0/7) 0% (0/7) 0% (0/6)a 0% (0/6) 1–4b
C57BL/6 s.c. 2 × 106 0% (0/9) 0% (0/9) 0% (0/9) 0% (0/9) 15
aIn our previous study, no tumors were observed after injection of 0.5–1 × 106 maGSC SSC5 cells into the hearts of six C57BL/6 mice treated with cyclosporine A (CsA) (10 mg/kg/
day) at 4 weeks after transplantation (8).
bIn each group, three mice were sacrificed after 1 week and three (+CsA) or four (−CsA) mice after 2 weeks. In addition, three mice in each group were analyzed 3 days after 
transplantation and no tumors were found. Sham-operated C57BL/6 mice (n = 3 for −CsA and n = 3 for +CsA, per time point) received PBS instead of maGSCs. As expected, no 
tumors were observed at days 3, 7, and 14.
5
Hübscher et al. NK Cells and Turigenicity of maGSCs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 67
ANOVA adjusted for E:T ratios) and the specific lysis was 25% at 
an E:T ratio of 24:1. In contrast, the specific lysis of maGSC SSC5 
cells was increased 3 days (24% at an E:T ratio of 24:1, P = 0.0016) 
but not 7  days after transplantation (18% at an E:T of 24:1, 
P = 0.1446, two-way ANOVA adjusted for E:T ratios). However, 
14 days (31% at an E:T ratio of 24:1, P = 1.42 × 10−5) and 28 days 
after transplantation (22% at an E:T ratio of 24:1, P = 0.0440, two-
way ANOVA adjusted for E:T ratios) the specific lysis of maGSC 
SSC5 cells was also higher than before transplantation. Thus, at 
day 14 after transplantation, the maximal activity of NK cells 
against both YAC-1 and maGSC SCC5 target cells was observed. 
These data indicate that the injection of the maGSCs SSC5 cells 
into the heart activates NK cells in RAG2−/− mice and results in an 
increased killing not only of YAC-1 but also of maGSC SSC5 cells.
In parallel to the chromium release assays, the expression of 
ligands for activating (CD112, CD155, RAE-1) and inhibitory 
(H2Kb, H2Db) NK receptors was determined by flow cytometry 
(Figure  2B). We analyzed the percentage of cells expressing 
these molecules as well as their mean fluorescence intensity. The 
expression of CD155, a ligand of DNAM-1, and RAE-1, a ligand 
of NKG2D, was higher in YAC-1 than in maGSC SSC5 cells. The 
major histocompatibility (MHC) class I molecules H2Kb and 
H2Db, which serve as ligands for mainly inhibitory Ly49 recep-
tors, were only weakly expressed on maGSC SSC5 cells. YAC-1 
cells are MHC class I-deficient cells of the H2a haplotype and were 
therefore not tested for H2Kb and H2Db expression. The maGSC 
SSC5 cells are also lacking H2Kq molecules, and none of the class 
I molecules (H2Kb, H2Db, or H2Kq) was decidedly induced by the 
stimulation with IFN-γ for 48 h (Figure 2C). These expression 
patterns contribute to the higher susceptibility of YAC-1 than 
maGSC SSC5 cells to killing by NK cells as demonstrated previ-
ously (20, 22).
csa suppresses Teratoma Formation
Next, the experiments were done in the same way but the recipients 
were treated in addition with CsA (20 mg/kg/day, i.p.). Overall, the 
frequency of tumors (Table 1) in RAG2−/− mice was lower than in 
RAG2−/−γc−/− mice (P = 0.0567, χ2 test). The treatment with CsA 
led to a highly significant decrease of the teratoma frequency in 
RAG2−/− and RAG2−/−γc−/− mice in comparison to the untreated 
animals (P = 0.0019, χ2 test). In the RAG2−/− mice treated with 
CsA, no teratomas were observed in the myocardium but in one 
mouse, a tumor was found on the heart (Table 1; Figure 1E). Only 
60% of the CsA-treated RAG2−/−γc−/− mice developed a teratoma 
upon intramyocardial transplantation of 5 ×  105 maGSC SSC5 
cells (Table  1). The teratomas were also smaller with a mean 
length of 1.3 mm and a mean width of 0.8 mm than those in the 
CsA-untreated RAG2−/−γc−/− mice (P < 0.001; Figure 1E). These 
results showed an unexpected but significant influence of CsA 
on the risk of teratoma formation after injection of maGSC SCC5 
cells into the heart in two immunodeficient mouse lines.
An immune histological analysis of the teratomas of the CsA-
treated RAG2−/−γc−/− mice indicated a reduced OCT4 expression 
in comparison to the non-CsA-treated group (Figure 3). Since 
OCT4 is a marker for undifferentiated PSCs, CsA seems to stimu-
late the differentiation of the transplanted undifferentiated cells.
cyclosporine Does not influence nK  
cell activity
Next, we analyzed the effect of CsA on the NK cell activity of 
RAG2−/− mice. Overall, when summarizing all time points after 
operation, the activity of NK cells from CsA-treated mice against 
YAC-1 target cells was slightly increased (w/o CsA: 52% at the 
E:T ratio of 24:1, n =  12; with CsA: 59%, n =  14; P =  0.0083, 
two-way ANOVA adjusted for E:T ratios). However, the killing of 
maGSC SSC5 target cells was not different in mice treated or not 
treated with CsA (w/o CsA: 24% at the E:T ratio of 24:1, n = 12; 
with CsA: 25%, n = 14; P = 0.4472, two-way ANOVA adjusted 
for E:T ratios). A separate analysis of the NK cell cytotoxicity at 
the different time points after transplantation indicated no differ-
ences for maGSC SSC5 targets, but an increased killing of YAC-1 
cells at day 7 (P = 0.0017) and day 28 after the transplantation 
(P = 0.0009, two-way ANOVA adjusted for E:T ratios) (Figure 4). 
The general pattern of NK cell activity after transplantation was 
not altered by the treatment with CsA. Thus, effects of CsA on the 
NK cell activity could not explain the effect of CsA on teratoma 
formation.
nK cell cytotoxicity is increased in  
Wild-type Mice upon Operation
The results obtained in RAG2−/− mice raised the questions whether 
the transplantation also activates NK cells in wild-type mice and 
whether NK cells become activated by the transplantation of 
FigUre 1 | Teratomas in immunodeficient rag2−/−γc−/− and rag2−/− mice with and without cyclosporine a (csa) treatment. (a) H&E staining of an 
intramyocardial teratoma after injection of undifferentiated multipotent adult germline stem cells (maGSCs) into immunodeficient RAG2−/−γc−/− mice. An overview is 
shown of the teratoma in the myocardium. (b) Cartilage and muscle cells indicate a mesodermal differentiation within this teratoma. (c) An endodermal 
differentiation is represented by intestinal epithelium. (D) The neural rosette represents an ectodermal differentiation in the teratoma. The scale bar in (a) represents 
500 µm and in (b–D) indicates 50 µm. (e) The hearts of mice (RAG2−/−γc−/− and RAG2−/−) were sectioned and analyzed at day 28 after injection of undifferentiated 
maGSCs in the heart. The maximal length and width of the tumor section in each heart was measured and mean + SD are shown. The groups RAG2−/−γc−/− − CsA 
(n = 8) and RAG2−/−γc−/− + CsA (n = 6), or RAG2−/− − CsA (n = 6) and RAG2−/− + CsA (n = 5), have been compared by two-way ANOVA for length and width. The 
respective P values are indicated.
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maGSCs or in response to the surgery. Therefore, we determined 
the NK cell activity in C57BL/6 wild-type mice after intramyocar-
dial transplantation of maGSC SSC5 cells. To differentiate effects 
of the operation (sham) from effects of the cell transplantation 
(Tx), we included sham-operated mice, which received an 
intramyocardial injection of 0.9% NaCl instead of cells. In addi-
tion to the treatment with CsA, we also included mice without 
the treatment with CsA. None of these mice developed a teratoma 
(Table 1). The NK cell activity was assayed 3, 7, and 14 days after 
transplantation since this was the most interesting phase with 
respect to cytotoxic NK cell activity in the RAG2−/− mice.
Mice that were not operated (day 0, untreated control) were 
included to determine the basal NK cell cytotoxicity (n =  3). 
Specific lysis of YAC-1 target cells was on average 32% at the E:T 
ratio of 12:1. In parallel, the specific lysis of the maGSC SSC5 cells 
was 9% (Figure 5A). Overall, the maGSCs were more resistant to 
killing by wild-type NK cells than YAC-1 cells (P = 2.85 × 10−10, 
two-way ANOVA adjusted for E:T ratios). When summarizing all 
FigUre 2 | cytotoxic activity of natural killer (nK) cells at different time points after intramyocardial transplantation of multipotent adult germline 
stem cell (magsc) ssc5 cells in rag2−/− mice. (a) A summary of means of specific lysis and the SEM is shown as determined by 51Cr-release assays of 
maGSC SSC5 (left panel) and YAC-1 target cells (right panel) by NK cells. The effector:target (E:T) ratio indicates the ratio of CD49+CD3- NK cells to maGSC SSC5 
or YAC-1 cells. The NK cells were isolated from RAG2−/− mice either before (0 days, n = 4) or at various days (3, 7, 14, or 28, n = 3 for each group) after 
intramyocardial transplantation of maGSC SSC5 cells and directly assayed without prior stimulation in vitro. (b) A flow cytometric analysis of ligands for activating 
and inhibitory NK receptors on maGSC SSC5 and YAC-1 cells was performed in parallel to the 51Cr-release assays. A summary (mean + SD, n = 9) is displayed of 
the percentage of cells expressing the indicated molecules (left panel) and their expression intensity [mean fluorescence intensity (MFI), right panel]. (c) The 
expression of major histocompatibility class I molecules was determined also after stimulation with interferon (IFN)-γ (100 ng/ml for 48 h) by flow cytometry. In these 
experiments, H2Kq was included since the cells have a mixed H2b and H2q background. RMA cells (H2b) served as control for the IFN-γ treatment. A summary 
(mean + SD, n = 3) is displayed of the percentage of cells expressing the indicated molecules (left panel) and their expression intensity (MFI, right panel).
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data of the three time points after operation, which are shown in 
Figure 5B (days 3, 7, and 14), this difference of killing remained 
unchanged (P = 2.06 × 10−43, n = 38 per cell line). On average, 
34% of YAC-1 and 15% of maGSC SSC5 cells were killed at the 
E:T ratio of 12:1. The target cell lysis, i.e., YAC-1 and maGSC 
SSC5 together, was affected by time (P = 1.31 × 10−10, two-way 
ANOVA adjusted for E:T ratios, day 3: n =  24, day 7: n =  28, 
day 14: n =  24). On average, specific lysis of both targets was 
18% at day 3, 25% at day 7, and 30% at day 14 after the opera-
tion. However, killing was not different when a sham operation 
was compared to Tx (P = 0.6453, two-way ANOVA adjusted for 
E:T ratios, sham and Tx each n = 38). Furthermore, the killing 
of target cells was also not affected by the treatment with CsA 
(P = 0.2085, two-way ANOVA adjusted for E:T ratios, w/o CsA: 
n = 40; with CsA: n = 36). When YAC-1 and maGSC SSC5 target 
cells were analyzed separately, similar results were obtained, 
indicating a significant dependence of killing on the time after 
operation (P = 2.77 × 10−28 for YAC-1 and P = 0.0107 for maGSC 
SSC5 cells, two-way ANOVA adjusted for E:T ratios), but not on 
the type of operation (sham versus Tx) or on the treatment with 
CsA.
Similar to results obtained with NK cells of RAG2−/− mice, the 
killing of YAC-1 cells by NK cells of wild-type mice was reduced 
at day 3 (P = 1.45 × 10−9), but increased at day 14 (P = 0.0212) 
FigUre 3 | The proportion of OcT4-positive cells is reduced in 
teratomas from cyclosporine a (csa)-treated mice. (a,c) H&E staining 
of representative teratomas grown in a RAG2−/−γc−/− mouse not treated (a) or 
treated with CsA (c). (b,D) On adjacent sections, OCT4 expression was 
determined by immunohistochemistry. The pictures are representative for the 
teratomas obtained in the RAG2−/−γc−/− mice treated or not treated with CsA. 
Scale bar, 50 µm.
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and unchanged at day 7 (P = 0.6712, two-way ANOVA adjusted 
for E:T ratios). The cell transplantation, when compared to 
the sham operation, had no significant effect on the killing of 
YAC-1 targets, except at day 14 showing a slight increase from 
42% (sham: n = 6) to 45% (Tx: n = 6) at the E:T ratio of 12:1 
(P  =  0.0178, two-way ANOVA adjusted for E:T ratios). This 
difference was also observed when the CsA-treated recipients 
were excluded from the analysis with 46% (sham, n = 3) versus 
50% (Tx, n = 3) specific lysis of YAC-1 targets at the E:T ratio of 
12:1 (P = 3.49 × 10−05, two-way ANOVA adjusted for E:T ratios). 
Effects of the treatment with CsA were rather complex for the 
various time points after transplantation. At day 3, the killing of 
maGSC SSC5 (P = 0.0002) and YAC-1 cells (P = 0.0085, two-way 
ANOVA adjusted for E:T ratios) was higher by NK cells of mice 
treated with CsA than untreated mice. The same was observed at 
day 7 for YAC-1 targets (P = 0.0013, two-way ANOVA adjusted 
for E:T ratios). However, at day 14, the cytotoxic NK cell activ-
ity of mice treated with CsA against YAC-1 cells was reduced 
(P = 5.01 × 10−5, two-way ANOVA adjusted for E:T ratios). Thus, 
the effects of the stem cell transplantation on cytotoxic NK cell 
activity were present also in wild-type mice mainly due to the 
operation but not the transplanted cells. Notably, CsA had little 
effects on NK cell cytotoxicity when averaged over the complete 
time of treatment.
inflammatory response to heart surgery
When we determined the number of splenocytes in RAG2−/− 
mice before isolation of NK cells, we realized a dependency on 
the time point after operation (P =  0.0003, two-way ANOVA 
adjusted for treatment with CsA). Compared to non-operated 
control mice, cell numbers were decreased at day 3 (P = 0.0107) 
but increased at day 7 (P = 0.0172) and 14 (P = 0.0287, Student’s 
t-tests) after the operation (Figure 6A). This likely indicates an 
early recruitment of immune cells from the spleen to a site of 
inflammation, such as the operation wound of the heart, and a 
lymphocytosis at later stages. The treatment with CsA overall 
increased the number of splenocytes (P  =  0.0304, two-way 
ANOVA adjusted for the time after operation), but at no single 
time point the difference reached statistical significance (Figure 
S1A in Supplementary Material).
To further analyze the postoperative inflammation, we 
determined several cytokines in the serum of the mice. The pro-
inflammatory cytokines TNF-α and IL-1b, and the Th2 cytokine 
IL-4 were not detectable systemically (data not shown). The IL-6 
concentration in serum was dependent on the time after opera-
tion (P = 0.0013; H test) and was increased at day 3 compared 
to controls (P = 0.0081, U test), indicating an early but transient 
inflammatory response after the operation (Figure 6C). In addi-
tion, IL-6 was high (1.602 pg/ml) in a single mouse at day 28, 
in which a teratoma was developed (Figure  6C). The systemic 
concentration of the Th1 cytokine IFN-γ, which can be produced, 
e.g., by activated NK cells, did not show a dependency on the time 
after operation (P = 0.6422, H test) and was not increased at any 
single time point when compared to control mice (Figure 6E). 
Similarly, the Th17 cytokine IL-17A was not increased in a 
time-dependent manner after operation (P =  0.4356, H tests) 
(Figure 6G). Moreover, none of the cytokine concentrations was 
dependent on the treatment with CsA except IL-17A, which was 
overall slightly increased in mice treated with CsA (542 ±  190 
versus 728 ±  213  pg/ml, P =  0.0080, H test) (Figure S1D in 
Supplementary Material). Only at day 7 after transplantation, the 
difference reached statistical significance for a single time point 
(P =  0.0495, U test). However, the relevance of this difference 
remains unclear.
Similarly, we determined the number of splenocytes before 
isolation of NK cells in C57BL/6 wild-type mice and found again a 
dependency on the time point after operation (P = 3.00 × 10−8, one-
way ANOVA) and the post hoc test indicated a difference between 
the three time points (days 3, 7, and 14) (Figure 6B). The number 
of splenocytes remained significantly different when adjusted for 
the type of operation (sham versus Tx: P = 4.07 × 10−8) or the 
treatment with CsA (P = 1.23 × 10−9). Overall, neither the type of 
operation (P = 0.1937) nor the treatment with CsA (P = 0.1167) 
had a significant effect on the number of splenocytes. Compared 
to untreated control mice (day 0), the number of splenocytes was 
reduced at day 3 (P = 0.0001) and 7 (P = 0.0027) but increased at 
day 14 (P = 0.0300, Student’s t-tests) after operation (Figure 6B). 
This pattern was similar to the results obtained in RAG2−/− mice 
(Figure 6A). At day 3, the number of splenocytes was affected by 
the CsA treatment (P = 0.0070, two-way ANOVA adjusted for the 
type of operation) (Figure S2A in Supplementary Material). It was 
reduced in mice treated with CsA when compared to mice not 
receiving CsA (P = 0.0031, Student’s t-test). At day 7, the number 
of splenocytes was affected by the type of operation (P = 0.0474, 
two-way ANOVA adjusted for CsA treatment) (Figure S2A in 
Supplementary Material) and higher in Tx mice compared to 
sham-operated mice (P = 0.0303, Student’s t- test).
The systemic concentration of IL-6 was increased only in 
three C57BL/6 wild-type mice after operation (Figure  6D) 
FigUre 4 | comparison of the killing of multipotent adult germline stem cell (magsc) ssc5 and Yac-1 target cells by natural killer (nK) cells of 
rag2−/− mice treated or not treated with cyclosporine a (csa). A summary of means of specific lysis and the SEM is shown as determined by 51Cr-release 
assays of maGSC SSC5 (left panels) and YAC-1 target cells (right panels) by NK cells. The NK cells were isolated from transplanted (Tx) RAG2−/− mice receiving 
(+CsA) or not receiving (−CsA) the immunosuppressant CsA (20 mg/kg/day) at various days (3, 7, 14, or 28) after transplantation (n = 3 for each group). The results 
of the transplanted but not CsA-treated (−CsA) mice have been also displayed in Figure 3. The groups (Tx −CsA and Tx +CsA) have been compared by two-way 
ANOVA adjusted for E:T ratios and the respective P values are indicated.
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FigUre 5 | cytotoxic activity of natural killer (nK) cells at different time points after intramyocardial transplantation of multipotent adult germline 
stem cell (magsc) ssc5 cells in c57bl/6 mice. A summary of means of specific lysis and the SEM is shown as determined by 51Cr-release assays of maGSC 
SSC5 (left panels) and YAC-1 target cells (right panels) by NK cells. (a) The NK cells were isolated from C57BL/6 control mice (day 0) or (b) at various days (3, 7, or 
14) after operation and directly assayed without prior stimulation in vitro. The NK cells were isolated from mice that received an intramyocardial transplantation of 
maGSC SSC5 cells (Tx) or sham-operated (sham) mice. The mice were treated (+CsA) or not treated (−CsA) with the immunosuppressant cyclosporine A (CsA) 
(20 mg/kg/day) (n = 3 per group and 4 for transplanted mice but not treated with CsA at day 7). The groups (−CsA and +CsA as well as sham and Tx) have been 
compared by two-way ANOVA adjusted for E:T ratios and the respective P values are indicated.
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and the concentrations of IFN-γ and IL-17A in the sera were 
not significantly dependent on the time point after operation 
(Figures 6F,H). IL-4 was not detected in the sera of these mice. The 
type of operation or the treatment with CsA had no effect on IL-6 
(Figure S2B in Supplementary Material) or IFN-γ (Figure  2C) 
concentration in the serum. At day 3, the IL-17A concentrations 
FigUre 6 | continued
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FigUre 6 | continued 
number of splenocytes and concentration of cytokines in non-operated control and transplanted rag2−/− (a,c,e,g) and c57bl/6 mice (b,D,F,h). The 
number of splenocytes was counted after lysis of erythrocytes and before isolation of natural killer cells in RAG2−/− (a) and C57BL/6 (b) mice not operated (day 0) 
and at various days (3, 7, 14, and for RAG2−/− mice 28) after transplantation. Differences in splenocyte numbers between not-operated controls and transplanted 
mice were compared by t-tests and the significant P values are displayed. The concentrations of cytokines IL-6 [(c) RAG2−/−; (D) C57BL/6], interferon-γ [(e) 
RAG2−/−; (F) C57BL/6], and IL-17A [(g) RAG2−/−; (h) C57BL/6] were measured by enzyme-linked immunosorbent assay in the sera of the mice. The mean + SD are 
indicated. The significant difference in IL-6 concentration between controls (non-operated) and RAG2−/− mice at day 3 after operation was calculated by the 
non-parametric U test.
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were higher in sham-operated than in Tx mice (P = 0.0159, H 
test) (Figure S2D in Supplementary Material). However, in view 
of the rather high variation of the concentration of this cytokine 
also at the other time points, the relevance of this finding remains 
questionable.
In summary, we found indications for a systemic inflamma-
tory response in the operated RAG2−/− mice and to a lesser extend 
in C57BL/6 wild-type mice. Although no clear polarization 
toward a Th1 response was found, our results showed that NK 
cells became activated in transplanted and sham-operated mice. 
This activation of NK cells could reduce the risk of teratomas in 
recipients receiving grafts of in vitro differentiated cells that might 
be contaminated with traces of PSCs.
DiscUssiOn
Pluripotent stem cells hold great promises for regenerative 
medicine as a source of cells and tissues for treatment of diseases 
such as macular degeneration or heart failure (33–35). The type 
of PSCs best suited for therapeutic purposes is currently debated 
(36). The use of ESCs is associated with ethical problems and 
they can only be used in allogenic transplant settings. In contrast, 
autologous iPSCs can be generated from patients, but they might 
be compromised in their genetic integrity by preexisting somatic 
mutations or mutations occurring during the reprograming 
process (11). The individual patient-specific iPSC lines would 
need to undergo complex procedures for quality control before 
being used as a source for autologous grafts, which are expected 
to be time consuming and expensive. For these reasons, only 
allogeneic transplants might be feasible for urgent and frequent 
medical indications and this would require the definition of an 
appropriate immunosuppressive therapy for the recipients (37). 
Besides the rejection of grafts, the formation of teratomas by 
residual PSCs within a graft is a major risk associated with the 
transplantation of PSC-derived cells or tissues (10). However, this 
risk would be increased in autologous transplant settings or in 
immunosuppressed recipients of allogeneic grafts (29, 38).
In this study, we have investigated the intramyocardial trans-
plantation of murine maGSCs, which are an alternative PSC type 
that can be obtained by ethically acceptable procedures from 
adult SSCs without the need of genetic manipulation.
First, we addressed the question whether the site of trans-
plantation affects the risk of teratomas arising from maGSCs. 
Our previous studies showed that undifferentiated maGSC 
SSC5 cells formed teratomas in immunodeficient mice after 
subcutaneous injection (7, 21). Moreover, further maGSC lines 
from other mouse strains were also capable to form teratomas in 
immunodeficient recipients after subcutaneous injection (22). In 
partially allogeneic C57BL/6 wild-type mice immunosuppressed 
with CsA, however, no teratomas were found within 4  weeks 
after transplantation of maGSCs SCC5 cells into the heart (8). 
We now show that teratomas were formed regularly also in 
the heart of immunodeficient recipients after intramyocardial 
injection of maGSC SSC5 cells. Moreover, additional teratomas 
at distant sites occurred in 75% of the RAG2−/−γc−/− recipients. 
The microenvironment of the heart has therefore no specific 
cardio-instructive potential for maGSCs. Mouse ESCs have 
been reported to differentiate upon transplantation in infarcted 
myocardium into cardiomyocytes, vascular smooth muscle, and 
endothelial cells and to improve cardiac structure and function 
(39). However, others studies emphasized that ESCs need to be 
differentiated before transplantation to avoid teratoma formation 
in the heart (40). On the other hand, the maGSCs were rejected 
in our study also after subcutaneous injection into immunocom-
petent C57BL/6 mice. Since, the maGSC SSC5 line was derived 
from a mouse with a mixed background (7), a rejection of the 
partially allogenic maGSCs by the immunocompetent C57BL/6 
recipients had to be expected. However, recipients treated with 
CsA for immunosuppression also rejected the cells. This demon-
strates that the risk of rejection does not differ after subcutaneous 
and intramyocardial transplantation and it suggests that non-T 
cells mediate the rejection of the maGSCs because T cells are the 
main targets of CsA. We have previously shown that NK cells 
can contribute to the rejection of PSCs, including ESCs, iPSCs, 
and maGSCs, after subcutaneous injection although they were 
not sufficient to prevent teratoma growth completely (20, 22, 29). 
After intramyocardial transplantation of maGSCs, we found now 
a reduced frequency and a reduced size of teratomas in T and 
B-cell-deficient RAG2−/− recipients compared to additionally NK 
cell-deficient RAG2−/−γc−/− mice. This indicates that NK cells 
impair the growth of teratomas not only in the subcutaneous 
tissue but also in the heart.
Initially, the effect of NK cells on PSCs has been debated and 
some studies reported resistance or very low susceptibility of 
the stem cells (41, 42), while others and we found PSCs to be 
highly susceptible to killing by NK cells (20, 22, 28). The conflict-
ing results appear to reflect mainly differences in the activation 
status of NK cells. We have recently shown that human iPSCs are 
largely resistant to resting allogenic as well as syngeneic NK cells 
but were readily killed by IL-2-activated NK cells (30). Moreover, 
we demonstrated that activation of murine NK cells in vivo by 
poly (I:C) impaired teratoma growth (22). The killing of murine 
PSCs was mediated in part by the activating NK receptor NKG2D 
(20, 22, 28), while killing of human iPSCs were more dependent 
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on the activating NK receptor DNAM-1 (30). The maGSC SSC5 
expressed some ligands for NKG2D and DNAM-1 but only low 
levels of MHC class I molecules that function as ligands for 
inhibitory NK receptors. This expression pattern is similar to 
other PSCs (21, 22), and it could contribute to the susceptibility 
of the maGSCs to killing by activated NK cells. Exposure to IFN-γ 
for 48 h was not sufficient to induce the expression of MHC class 
I molecules on the maGSCs suggesting that a pro-inflammatory 
milieu in  vivo would also not render the undifferentiated cells 
resistant to NK cells.
Upon differentiation, however, the expression MHC class 
I molecules increases on most cell types rendering them less 
susceptible to NK cells (22). In vivo, injected PSCs can escape 
rejection by NK cells by differentiation into the various cell 
types present in teratomas. This, however, is expected to increase 
the risk of rejection of allografts by alloreactive CTL and other 
mechanisms of the adaptive immune system. Therefore, NK cell 
can frequently not prevent teratoma growth completely upon 
injection of larger amounts of PSCs, whereas no teratomas occur 
in immunocompetent recipients receiving allogeneic PSCs.
Natural killer cells are an interesting player in the transplanta-
tion of PSC-derived grafts because activated NK cells can target 
even autologous PSCs (30), while differentiated cells are normally 
resistant at least to autologous NK cells. NK cells might therefore 
be able to target specifically residual PSCs in PSC-derived grafts. 
Thereby, they potentially increase the safety of PSC-derived grafts 
(29), if their activity is not impaired by the immunosuppressive 
treatment given to the recipients. In this study, we have shown that 
NK cells become activated in RAG2−/− and in wild-type recipients 
upon transplantation. The in  vivo-activated NK cells killed the 
NK cell target cell line YAC-1 and, although less efficiently, the 
maGSCs. Notably, the maGSCs were largely resistant to freshly 
isolated NK cells from untreated control mice. The highest activ-
ity was observed 2  weeks after the transplantation. One week 
after the transplantation, we observed a systemic inflammatory 
response with a slightly increased serum concentration of IL-6 
and a lymphocytosis in the spleens of RAG2−/− mice. In wild-type 
mice, the lymphocytosis occurred later, 2 weeks after transplanta-
tion, and the IL-6 response was restricted to individual mice. No 
clear systemic polarization toward a Th1, Th2, or Th17 cytokine 
profile was observed at the systemic level in the serum of the 
recipients. However, in the cause of the inflammatory response, 
the NK cell activity increased in RAG2−/− and wild-type recipients. 
Experiments in wild-type recipients furthermore demonstrated 
that the sham operation procedure was sufficient to activate the 
NK cells. It remains to be investigated whether a less traumatic 
transplantation procedure than open-chest surgery, such as ultra-
sound-guided injection of cells into the heart, would also activate 
the NK cell system. If not, the risk of teratoma growth could be 
higher in NK cell competent recipients than in the experiments 
reported here. Importantly, the activation of NK cells was not 
impaired by treatment of the recipients with CsA. This could 
explain why CsA is not sufficient to allow for an engraftment of 
the partially allogeneic maGSCs in C57BL/6 recipients. This is in 
line with our previous results obtained with an ESC line, which 
has been usually rejected in CsA-treated allogeneic recipients 
(20). However, effects of CsA and further immunosuppressive 
drugs on the peripheral NK cell repertoire and NK cell activity 
have been observed in transplant patients (43) and need to be 
further considered when developing allogeneic PSC-based trans-
plant therapies. Recently, teratocarcinomas have been observed 
after allogeneic transplantation of iPSC-derived cardiac tissue 
sheets in syngeneic C57BL/6 and with tacrolimus-treated allo-
geneic BALB/c mice but not in the immunocompetent BALB/c 
recipients (44). The authors presented some evidence that the 
NK cell activity might have been suppressed by tacrolimus, and 
therefore, tacrolimus could be associated with a higher tumor risk 
than CsA after transplantation of PSC-derived grafts.
Notably, we observed in our study also that the CsA treatment 
impaired the teratoma growth in immunodeficient recipients. In 
teratomas from CsA-treated RAG2−/−γc−/− mice, we observed a 
reduced expression of OCT4, which is an essential transcription 
factor in PSCs. This suggests that CsA could inhibit the survival 
or proliferation of PSCs or promote their differentiation into 
non-proliferating tissues. Interestingly, it has been reported that 
CsA can indeed enhance the cardiac differentiation of mouse 
ESCs (45) and mouse and human iPSCs (46). Moreover, a 
reduced proliferation of other stem cell types including neural 
stem cells and mesenchymal stem cells has been observed 
[reviewed in Ref. (47)]. These results indicate that direct effects 
of immunosuppressive drugs on PSCs and PSC-derived grafts 
need to be considered. In future studies, different immunosup-
pressive or immunomodulatory treatments (48–51) need to be 
compared to define the best regimen allowing for engraftment of 
allogeneic PSC-derived transplants without increasing the risk 
of tumorigenicity.
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